Literature DB >> 10194075

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response.

J D Fuller1, D E Craven, K A Steger, N Cox, T C Heeren, D Chernoff.   

Abstract

We assessed the effect of influenza vaccination on plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and the impact of age, plasma HIV-1 RNA level, CD4 cell count, and anti-HIV therapy on immune response. Forty-nine adults (mean age, 38.7 years; mean CD4 cell count +/- SD, 190 +/- 169/mL; mean plasma HIV-1 RNA level +/- SD, 154,616 +/- 317,192 copies/mL) were immunized. Elevations of > or = 0.48 log in plasma HIV-1 RNA levels occurred in two (4%) of 49 subjects within 4 weeks of vaccination. A fourfold or greater increase in antibody titer occurred in 13 (45%) of 29 subjects, correlating directly with CD4 cell count (P = .002) and inversely with plasma HIV-1 RNA level (P = .034). By multivariate analysis, CD4 cell count was a stronger predictor of antibody response than was plasma HIV-1 RNA level. We conclude that increases in plasma HIV-1 RNA levels following influenza vaccination are rare and transient and that antibody response is impaired with CD4 cell counts of < 100/mL and plasma HIV-1 RNA levels of > 100,000 copies/mL. Prospective trials are needed to evaluate the impact of highly active therapy on immune response after vaccination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194075     DOI: 10.1086/515170

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.

Authors:  Adriana Weinberg; Lin-Ye Song; Terence Fenton; Sharon A Nachman; Jennifer S Read; Julie Patterson-Bartlett; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

Review 2.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

3.  Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; David Chien Lye; Eng-Eong Ooi; Yee-Sin Leo
Journal:  Hum Vaccin Immunother       Date:  2017-02-17       Impact factor: 3.452

Review 4.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

5.  Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.

Authors:  Shikha Garg; Prasert Thongcharoen; Prabda Praphasiri; Anupong Chitwarakorn; Pornchai Sathirapanya; Stefan Fernandez; Kamonthip Rungrojcharoenkit; Wannee Chonwattana; Philip A Mock; Wichuda Sukwicha; Jacqueline M Katz; Marc-Alain Widdowson; Marcel E Curlin; Robert V Gibbons; Timothy H Holtz; Fatimah S Dawood; Sonja J Olsen
Journal:  Clin Infect Dis       Date:  2015-10-20       Impact factor: 9.079

6.  Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination.

Authors:  Zhenwu Luo; Lei Ma; Lumin Zhang; Lisa Martin; Zhuang Wan; Stephanie Warth; Andrew Kilby; Yong Gao; Pallavi Bhargava; Zhen Li; Hao Wu; Eric G Meissner; Zihai Li; J Michael Kilby; Guoyang Liao; Wei Jiang
Journal:  Vaccine       Date:  2015-12-22       Impact factor: 3.641

7.  The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals.

Authors:  Anna M Powell; Zhenwu Luo; Lisa Martin; Zhuang Wan; Lei Ma; Guoyang Liao; Yuxia Song; Xiaochun Li; J Michael Kilby; Lei Huang; Wei Jiang
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

8.  Enhanced cellular immunity in macaques following a novel peptide immunotherapy.

Authors:  S Chea; C J Dale; R De Rose; I A Ramshaw; S J Kent
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children.

Authors:  Myron J Levin; Lin-Ye Song; Terrence Fenton; Sharon Nachman; Julie Patterson; Robert Walker; George Kemble; Maria Allende; Micki Hultquist; Tingting Yi; Barbara Nowak; Adriana Weinberg
Journal:  Vaccine       Date:  2008-06-10       Impact factor: 3.641

10.  International Travel: Recommendations for the HIV-infected Patient.

Authors:  Lisa A Spacek; Thomas C Quinn
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.